Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2203 - Mutational profiles in paired primary tumours and metastases in colorectal cancer patients: an NGS study of the Hellenic Cooperative Oncology Group


08 Oct 2016


Poster Display


George Pentheroudakis


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


G. Pentheroudakis1, V. Kotoula1, V. Kourvelos2, E. Charalambous1, V. Karavasilis1, E. Giannoulatou3, G. Tsoulfas1, E. Pazarli1, G. Glantzounis1, P. Papakostas1, E. Samantas1, D. Pectasides1, G. Fountzilas1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Biostatistics, Health Data Specialists, Ltd, Athens/GR
  • 3 Bioinformatics, Victor Chang Cardiac Research Institute, Darlinghurst/AU


Abstract 2203


Clonal heterogeneity in cancer contributes to resistance to therapy. The comparison of the genetic profile of primary tumours with that of metastases will inform clinical decision-making for advanced colorectal cancer patients.


Formalin-fixed paraffin-embedded colorectal adenocarcinoma from primary tumours (CRCp) and metastases (CRCm) from 82 patients managed according to HeCOG protocols were assessed. Next Generation Sequencing (Ion PROTON) was applied for mutational profiling of 51 cancer-related genes and 6 non-coding RNAs (444 amplicons, 48000 bases, median reading depth > 1300x). 57 patients had synchronous and 25 metachronous metastases. Intervening lines of therapy between primary tumour to resection of metastases were administered in 46 patients.


The most frequently mutated genes in CRCp were TP53 45%, KRAS 32%, APC 27%, IGF1R 8.5%, CDH1 8.5%, whereas in CRCm TP53 48%, APC 30%, KRAS 27%, IGF1R 9.8%, PIK3CA 9.8%. Concordance rates between paired CRCp and CRCm were high (77-96%) for the commonly mutated genes. A trend for increasing discordance of the mutational status was observed in metachronous as compared to synchronous metastases.Higher mutational discordance was observed when therapy intervened between CRCp and CRCm. We observed co-existence of mutational discordance in genes related to several functional groups, suggesting clonal divergence affecting the genome diffusely. We will present more data on mutated allele frequencies in shared as well as in private mutations in CRCp and CRCm and analyse the impact on patient outcome.

%Mutational discordance CRCp vs CRCm by time and exposure to therapy

GENE Metachronous Synchronous Not exposed to tx Exposed to tx
p53 31 18 15 28
APC 24 12 10 20
KRAS 9 4 2 6
IGF1R 8 4 0 10
CDH1 10 8 0 14
HER4 12 2 0 11
SMAD4 12 4 1 11
BRAF 8 2 0 6
NRAS 5 2 0 4


Although a high concordance rate for frequently mutated genes was seen in CRCp versus CRCm, a trend was observed for increasing discordance with metachronous appearance of metastases and with prior exposure to antineoplastic therapy.

Clinical trial identification

Legal entity responsible for the study

Hellenic Cooperative Oncology Group


Hellenic Cooperative Oncology Group


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings